Alternate-Day Buprenorphine Administration. Phase IV - 5

Completed · Phase 2

Conditions studied: Opioid-Related Disorders

In brief

The purpose of this study is to determine if three times a subject's daily maintenance dose will hold for 72 hours without changes in agonist and antagonist effects.

Key facts

Study ID

NCT00000223

Run by

National Institute on Drug Abuse (NIDA)

People needed

0

Starts

1993-06-01

Last updated by the study team

2005-06-24

Who can join

Age: 20 and older, up to 49. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Treatment Research Center — Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.